Cutaneous immunization: An evolving paradigm in influenza vaccines

Expert Opinion on Drug Delivery

Volumn 11, Issue 4, 2014, Pages 615-627

  Gill, Harvinder S ^a   Kang, Sang Moo ^b   Quan, Fu Shi ^c   Compans, Richard W ^d  

^a Department of Electrical and Computer Engineering   (United States)

^b GEORGIA STATE UNIVERSITY   (United States)

^c Kyung Hee University Hospital   (South Korea)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cutaneous; Immunization; Influenza; Review

Indexed keywords

DNA VACCINE; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; SUBUNIT VACCINE; TRIPLE VACCINE;

CLINICAL TRIAL (TOPIC); CUTANEOUS DRUG ADMINISTRATION; DNA IMMUNIZATION; DRUG FORMULATION; ELECTROPORATION; GENE GUN; GENE GUN IMMUNIZATION; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; JET INJECTOR; MICRONEEDLE; NONHUMAN; REVIEW; SINGLE DRUG DOSE; SKIN ABRASION; SKIN PENETRATION; STRATUM CORNEUM; THERMAL ABLATION DELIVERY DEVICE; ULTRASOUND;

ADMINISTRATION, CUTANEOUS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNIZATION; INFLUENZA VACCINES; INJECTIONS, INTRADERMAL; SKIN;

EID: 84897827302     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2014.885947     Document Type: Review

References (101)

1. Jenner E. An inquiry into the causes and effects of the variolæ vaccinæ, or cow-pox. The three original publications on vaccination against smallpox. The Harvard Classics, 1909-1914
2. Foege WH, Millar JD, Henderson DA. Smallpox eradication in West and Central Africa. Bull World Health Organ 1975;52(2):209-22
3. Sticchi L, Alberti M, Alicino C, et al. The intradermal vaccination: past experiences and current perspectives. J Prev Med Hyg 2010;51(1):7-14
4. Teunissen MBM. Intradermal immunization. Springer-Verlag, Dusseldorf, Germany;2012
5. Weniger BG, Papania MJ. Alternative vaccine delivery methods. In: Plotkin SA, Orenstein WA, Offit PA, editors, Vaccines. 6th edition. Elsevier, New York, NY; 2013. p. 1200-31
6. Pearson FE, McNeilly CL, Crichton ML, et al. Dry-coated live viral vector vaccines delivered by nanopatch microprojections retain long-term thermostability and induce transgene-specific T cell responses in mice. PLoS One 2013;8(7):e67888
7. Naik A, Kalia YN, Guy RH. Transdermal drug delivery: overcoming the skin's barrier function. Pharm Sci Technolo Today 2000;3(9):318-26
8. Bos JD, Kapsenberg ML. The skin immune system: progress in cutaneous biology. Immunol Today 1993;14(2):75-8
9. Glenn GM, Kenney RT, Ellingsworth LR, et al. Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin. Expert Rev Vaccines 2003;2(2):253-67
10. Romani N, Clausen BE, Stoitzner P. Langerhans cells and more: langerinexpressing dendritic cell subsets in the skin. Immunol Rev 2010;234(1):120-41
11. Sparber F, Tripp CH, Hermann M, et al. Langerhans cells and dermal dendritic cells capture protein antigens in the skin: possible targets for vaccination through the skin. Immunobiology 2010;215(9-10):770-9
12. Karande P, Arora A, Pham TK, et al. Transcutaneous immunization using common chemicals. J Control Release 2009;138(2):134-40
13. Tezel A, Paliwal S, Shen Z, et al. Low-frequency ultrasound as a transcutaneous immunization adjuvant. Vaccine 2005;23(29):3800-7
14. Hooper JW, Golden JW, Ferro AM, et al. Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Vaccine 2007;25(10):1814-23
15. Babiuk S, Baca-Estrada ME, Foldvari M, et al. Needle-free topical electroporation improves gene expression from plasmids administered in porcine skin. Mol Ther 2003;8(6):992-8
16. Laddy DJ, Yan J, Khan AS, et al. Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol 2009;83(9):4624-30
17. Skountzou I, Quan FS, Jacob J, et al. Transcutaneous immunization with inactivated influenza virus induces protective immune responses. Vaccine 2006;24(35-36):6110-19
18. Frolov VG, Seid RC Jr, Odutayo O, et al. Transcutaneous delivery and thermostability of a dry trivalent inactivated influenza vaccine patch. Influenza Other Respir Viruses 2008;2(2):53-60
19. Garg S, Hoelscher M, Belser JA, et al. Needle-free skin patch delivery of a vaccine for a potentially pandemic influenza virus provides protection against lethal challenge in mice. Clin Vaccine Immunol 2007;14(7):926-8
20. Gill HS, Andrews SN, Sakthivel SK, et al. Selective removal of stratum corneum by microdermabrasion to increase skin permeability. Eur J Pharm Sci 2009;38(2):95-103
21. Andrews SN, Zarnitsyn V, Bondy B, et al. Optimization of microdermabrasion for controlled removal of stratum corneum. Int J Pharm 2011;407(1-2):95-104
22. Mitragotri S. Current status and future prospects of needle-free liquid jet injectors. Nat Rev Drug Discov 2006;5(7):543-8
23. Fuller DH, Loudon P, Schmaljohn C. Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases. Methods 2006;40(1):86-97
24. Jones S, Evans K, McElwaine-Johnn H, et al. DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. Vaccine 2009;27(18):2506-12
25. Gill HS, Denson DD, Burris BA, et al. Effect of microneedle design on pain in human volunteers. Clin J Pain 2008;24(7):585-94
26. Prausnitz MR, Mikszta JA, Cormier M, et al. Microneedle-based vaccines. Curr Top Microbiol Immunol 2009;333:369-93
27. Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev 2012;64(14):1547-68
28. Gill HS, Prausnitz MR. Coating formulations for microneedles. Pharm Res 2007;24(7):1369-80
29. Gill HS, Prausnitz MR. Coated microneedles for transdermal delivery. J Control Release 2007;117(2):227-37
30. Kenney RT, Frech SA, Muenz LR, et al. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004;351(22):2295-301
31. La Montagne JR, Fauci AS. Intradermal influenza vaccination-can less be more? N Engl J Med 2004;351(22):2330-2
32. Birchall J, Coulman S, Pearton M, et al. Cutaneous DNA delivery and gene expression in ex vivo human skin explants via wet-etch micro-fabricated micro-needles. J Drug Target 2005;13(7):415-21
33. Park JH, Allen MG, Prausnitz MR. Biodegradable polymer microneedles: fabrication, mechanics and transdermal drug delivery. J Control Release 2005;104(1):51-66
34. Dean HJ. Epidermal delivery of protein and DNA vaccines. Expert Opin Drug Deliv 2005;2(2):227-36
35. Zaric M, Lyubomska O, Touzelet O, et al. Skin dendritic cell targeting via microneedle arrays laden with antigenencapsulated poly-D,L-lactide- coglycolide nanoparticles induces efficient antitumor and antiviral immune responses. ACS Nano 2013;7(3):2042-55
36. Zhu Q, Zarnitsyn VG, Ye L, et al. Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proc Natl Acad Sci USA 2009. 106(19):7968-73
37. Koutsonanos DG, del Pilar Martin M, Zarnitsyn VG, et al. Transdermal influenza immunization with vaccinecoated microneedle arrays. PLoS One 2009;4(3):e4773
38. Quan FS, Kim YC, Vunnava A, et al. Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization. J Virol 2010;84(15):7760-9
39. Quan FS, Kim YC, Yoo DG, et al. Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin. PLoS One 2009;4(9):e7152
40. Kim YC, Quan FS, Yoo DG, et al. Improved influenza vaccination in the skin using vaccine coated microneedles. Vaccine 2009;27(49):6932-8
41. Choi HJ, Yoo DG, Bondy BJ, et al. Stability of influenza vaccine coated onto microneedles. Biomaterials 2012;33(14):3756-69
42. Choi HJ, Bondy BJ, Yoo DG, et al. Stability of whole inactivated influenza virus vaccine during coating onto metal microneedles. J Control Release 2013;166(2):159-71
43. Fernando GJ, Chen X, Primiero CA, et al. Nanopatch targeted delivery of both antigen and adjuvant to skin synergistically drives enhanced antibody responses. J Control Release 2012;159(2):215-21
44. Koyama S, Aoshi T, Tanimoto T, et al. Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes. Sci Transl Med 2010;2(25):25ra24
45. Gross PA. Reactogenicity and immunogenicity of bivalent influenza vaccine in one- and two-dose trials in children: a summary. J Infect Dis 1977;136(Suppl):S616-25
46. Gross PA, Ennis FA, Gaerlan PF, et al. A controlled double-blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product influenza vaccines in children. J Infect Dis 1977;136(5):623-32
47. Gross PA, Ennis FA. Influenza vaccine: split-product versus whole-virus types-How do they differ. N Engl J Med 1977;296(10):567-8
48. Ellebedy AH, Webby RJ. Influenza vaccines. Vaccine 2009;27(Suppl 4):D65-8
49. Marcelin G, Bland HM, Negovetich NJ, et al. Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A (H1N1) 2009 virus in an age-dependent manner. J Infect Dis 2010;202(11):1634-8
50. McElhaney JE. Influenza vaccine responses in older adults. Ageing Res Rev 2011;10(3):379-88
51. Koutsonanos DG, del Pilar Martin M, Zarnitsyn VG, et al. Serological memory and long-term protection to novel H1N1 influenza virus after skin vaccination. J Infect Dis 2011;204(4):582-91
52. Sullivan SP, Koutsonanos DG, Del Pilar Martin M, et al. Dissolving polymer microneedle patches for influenza vaccination. Nat Med 2010;16(8):915-20
53. Koutsonanos DG, Vassilieva EV, Stavropoulou A, et al. Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection. Sci Rep 2012;2:357
54. Kommareddy S, Baudner BC, Bonificio A, et al. Influenza subunit vaccine coated microneedle patches elicit comparable immune responses to intramuscular injection in guinea pigs. Vaccine 2013;31(34):3435-41
55. Laurent PE, Bonnet S, Alchas P, et al. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine 2007;25(52):8833-42
56. Atmar RL, Patel SM, Keitel WA. Intanza ((R)): a new intradermal vaccine for seasonal influenza. Expert Rev Vaccines 2010;9(12):1399-409
57. Ansaldi F, de Florentiis D, Durando P, et al. Fluzone((R)) Intradermal vaccine: a promising new chance to increase the acceptability of influenza vaccination in adults. Expert Rev Vaccines 2012;11(1):17-2
58. Kang SM, Song JM, Quan FS, et al. Influenza vaccines based on virus-like particles. Virus Res 2009;143(2):140-6
59. Assad S, Francis A. Over a decade of experience with a yeast recombinant hepatitis B vaccine. Vaccine 1999;18(1-2):57-67
60. McAleer WJ, Buynak EB, Maigetter RZ, et al. Human hepatitis B vaccine from recombinant yeast. Nature 1984;307(5947):178-80
61. Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;56(RR-2):1-24
62. Moron VG, Rueda P, Sedlik C, et al. In vivo, dendritic cells can cross-present virus-like particles using an endosome-to-cytosol pathway. J Immunol 2003;171(5):2242-50
63. Lopez-Macias C. Virus-like particle (VLP)-based vaccines for pandemic influenza: performance of a VLP vaccine during the 2009 influenza pandemic. Hum Vaccin Immunother 2012;8(3):411-14
64. Lopez-Macias C, Ferat-Osorio E, Tenorio-Calvo A, et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine 2011;29(44):7826-34
65. Khurana S, Wu J, Verma N, et al. H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans. J Virol 2011;85(21):10945-54
66. Quan FS, Vunnava A, Compans RW, et al. Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. PLoS One 2010;5(2):e9161
67. Kim YC, Quan FS, Song JM, et al. Influenza immunization with trehalosestabilized virus-like particle vaccine using microneedles. Procedia Vaccinol 2010;2(1):15-19
68. Song JM, Kim YC, Barlow PG, et al. Improved protection against avian influenza H5N1 virus by a single vaccination with virus-like particles in skin using microneedles. Antiviral Res 2010;88(2):244-7
69. Quan FS, Kim YC, Compans RW, et al. Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles. J Control Release 2010;147(3):326-32
70. Quan FS, Kim YC, Song JM, et al. Long-term protective immunity from an influenza virus-like particle vaccine administered with a microneedle patch. Clin Vaccine Immunol 2013;20(9):1433-9
71. Donnelly JJ, Friedman A, Martinez D, et al. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat Med 1995;1(6):583-7
72. Drape RJ, Macklin MD, Barr LJ, et al. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 2006;24(21):4475-81
73. Babiuk LA, Pontarollo R, Babiuk S, et al. Induction of immune responses by DNA vaccines in large animals. Vaccine 2003;21(7-8):649-58
74. MacGregor RR, Boyer JD, Ugen KE, et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998;178(1):92-100
75. Haensler J, Verdelet C, Sanchez V, et al. Intradermal DNA immunization by using jet-injectors in mice and monkeys. Vaccine 1999;17(7-8):628-38
76. Yager EJ, Dean HJ, Fuller DH. Prospects for developing an effective particle-mediated DNA vaccine against influenza. Expert Rev Vaccines 2009;8(9):1205-20
77. Falo LD Jr. Targeting the skin for genetic immunization. Proc Assoc Am Physicians 1999;111(3):211-19
78. Bragstad K, Vinner L, Hansen MS, et al. A polyvalent influenza A DNA vaccine induces heterologous immunity and protects pigs against pandemic A(H1N1) pdm09 virus infection. Vaccine 2013;31(18):2281-8
79. Chen X, Kask AS, Crichton ML, et al. Improved DNA vaccination by skintargeted delivery using dry-coated densely-packed microprojection arrays. J Control Release 2010;148(3):327-33
80. Gill HS, Soderholm J, Prausnitz MR, et al. Cutaneous vaccination using microneedles coated with hepatitis C DNA vaccine. Gene Ther 2010;17(6):811-14
81. Kim YC, Song JM, Lipatov AS, et al. Increased immunogenicity of avian influenza DNA vaccine delivered to the skin using a microneedle patch. Eur J Pharm Biopharm 2012;81(2):239-47
82. Kim YC, Quan FS, Compans RW, et al. Formulation of microneedles coated with influenza virus-like particle vaccine. AAPS PharmSciTech 2010;11(3):1193-201
83. Song JM, Kim YC, O E, et al. DNA vaccination in the skin using microneedles improves protection against influenza. Mol Ther 2012;20(7):1472-80
84. Kim YC, Yoo DG, Compans RW, et al. Cross-protection by co-immunization with influenza hemagglutinin DNA and inactivated virus vaccine using coated microneedles. J Control Release 2013;172(2):579-88
85. Prow TW, Chen X, Prow NA, et al. Nanopatch-targeted skin vaccination against West Nile Virus and Chikungunya virus in mice. Small 2010;6(16):1776-84
86. Kask AS, Chen X, Marshak JO, et al. DNA vaccine delivery by densely-packed and short microprojection arrays to skin protects against vaginal HSV-2 challenge. Vaccine 2010;28(47):7483-91
87. Weldon WC, Wang BZ, Martin MP, et al. Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. PLoS One 2010;5:9
88. Weldon WC, Zarnitsyn VG, Esser ES, et al. Effect of adjuvants on responses to skin immunization by microneedles coated with influenza subunit vaccine. PLoS One 2012;7(7):e41501
89. Kim YC, Quan FS, Yoo DG, et al. Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. J Infect Dis 2010;201(2):190-8
90. del Pilar Martin M, Weldon WC, Zarnitsyn VG, et al. Local response to microneedle-based influenza immunization in the skin. MBio 2012;3(2):e00012-12
91. Quan FS, Yoo DG, Song JM, et al. Kinetics of immune responses to influenza virus-like particles and dosedependence of protection with a single vaccination. J Virol 2009;83(9):4489-97
92. De Becker G, Sornasse T, Nabavi N, et al. Immunoglobulin isotype regulation by antigen-presenting cells in vivo. Eur J Immunol 1994;24(7):1523-8
93. Belyakov IM, Hammond SA, Ahlers JD, et al. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J Clin Invest 2004;113(7):998-1007
94. Hon H, Jacob J. Tracking dendritic cells in vivo: insights into DC biology and function. Immunol Res 2004;29(1-3):69-80
95. Ng HI, Fernando GJ, Kendall MA. Induction of potent CD8(+) T cell responses through the delivery of subunit protein vaccines to skin antigenpresenting cells using densely packed microprojection arrays. J Control Release 2012;162(3):477-84
96. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol 2004;172(5):2731-8
97. Pearton M, Allender C, Brain K, et al. Gene delivery to the epidermal cells of human skin explants using microfabricated microneedles and hydrogel formulations. Pharm Res 2008;25(2):407-16
98. Pearton M, Kang SM, Song JM, et al. Influenza virus-like particles coated onto microneedles can elicit stimulatory effects on Langerhans cells in human skin. Vaccine 2010;28(37):6104-13
99. Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine 2008;26(26):3197-208
100. Pearton M, Kang SM, Song JM, et al. Changes in human Langerhans cells following intradermal injection of influenza virus-like particle vaccines. PLoS One 2010;5(8):e12410
101. Pearton M, Pirri D, Kang SM, et al. Host responses in human skin after conventional intradermal injection or microneedle administration of virus-like-particle influenza vaccine. Adv Healthc Mater 2013;2(10):1401-10